Dr. Elena Vance, DO

Background

Dr. Elena Vance, DO is board-certified in internal medicine with a clinical focus on endocrinology and obesity medicine. Her practice emphasizes evidence-based pharmacologic management of type 2 diabetes, obesity, and related cardiometabolic conditions, with extensive experience using GLP-1 and dual GIP/GLP-1 receptor agonists.

Role at glp1versus.com

Dr. Vance is the designated medical reviewer for editorial content on glp1versus.com. She reviews drug profiles, head-to-head comparisons, condition pages, switching guides, and blog articles for clinical accuracy before publication and on a rolling basis as new FDA approvals, label changes, and pivotal trial results emerge.

Review covers: clinical trial citations, efficacy figures (A1C reduction, weight-loss percent, trial names and durations), FDA approval dates and NDA numbers, boxed warnings and contraindications, side-effect frequency data, and mechanism-of-action explanations.

Scope of review

• Drug profiles— all 11 GLP-1 medications profiled on this site (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Victoza, Trulicity, Bydureon, Byetta, Foundayo)
• Head-to-head comparisons— all published drug-vs-drug comparison pages
• Condition pages— GLP-1 for sleep apnea, heart risk, and MASH
• Switching guides— clinical considerations when transitioning between GLP-1 therapies
• Glossary— definitions of GLP-1, GIP, prior authorization, and related terms

Editorial independence

glp1versus.com is not owned by or affiliated with any pharmaceutical manufacturer, telehealth platform, or pharmacy. Dr. Vance’s review of content is editorially independent: nothing published on this site is influenced by advertiser relationships, affiliate revenue, or drug-company sponsorship.

For the site’s full editorial process and source hierarchy, see our methodology page.

Contact

Editorial corrections, factual disputes, or requests for additional source documentation can be raised by contacting the site team through the About page.